Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pardes Biosciences, Inc. - Common Stock (NQ:PRDS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 2.160 (5)
Ask (Size) 2.210 (250)
Prev. Close 2.160
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
From Foresite Capital
Via Business Wire
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
From MediPacific, Inc.
Via Business Wire

Performance

More News

Read More
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
From Kahn Swick & Foti, LLC
Via Business Wire
Why Pardes Biosciences Shares Are Rising Monday
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
From Kahn Swick & Foti, LLC
Via Business Wire
Recap: Pardes Biosciences Q1 Earnings
Via Benzinga
Pardes Biosciences Looks For Alternatives After Failed COVID-19 Study
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
From Brodsky & Smith LLC
Via GlobeNewswire
PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Pardes Biosciences, Inc. (NASDAQ:PRDS) Investor Alert: Investigation over Potential Wrongdoing
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
Investigation Announced for Investors Who Lost Money with Shares of Pardes Biosciences, Inc. (NASDAQ: PRDS)
Via SBWire
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Via Benzinga
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga

Frequently Asked Questions

Is Pardes Biosciences, Inc. - Common Stock publicly traded?
Yes, Pardes Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Pardes Biosciences, Inc. - Common Stock trade on?
Pardes Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pardes Biosciences, Inc. - Common Stock?
The ticker symbol for Pardes Biosciences, Inc. - Common Stock is PRDS on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.